CORONAVIRUS - Oficina Española de Patentes
←
→
Transcripción del contenido de la página
Si su navegador no muestra la página correctamente, lea el contenido de la página a continuación
CORONAVIRUS
DIAGNÓSTICO Y TERAPIA
PATENTES
EN HUMANOS
0
2018-2020
NIPO 116-20-001-5
La pandemia de COVID-19 que ha originado el Desde la Oficina Española de Patentes y
nuevo Coronavirus SARS-CoV-2, detectado por Marcas, y en cumplimiento de nuestro doble
primera vez en diciembre de 2019 en Wuhan objetivo de proteger y fomentar la innovación
(China), ha generado una gran actividad en tecnológica en nuestro país, así como de
sectores sociales diversos con el objetivo divulgar la información técnica que contienen
común de combatir y paliar los efectos que las patentes a través de sus servicios de
estamos padeciendo. Dicha actividad ha sido Información Tecnológica, hemos realizado este
capitalizada, como es evidente, por el sector nuevo Boletín de Vigilancia Tecnológica, que se
sanitario, que busca la mejor manera de tratar suma a los quince Boletines VT que venimos
y diagnosticar a los enfermos, pero también se publicando desde el año 2000 con periodicidad
está manifestando en las grandes empresas y trimestral. Nuestro objetivo es dar a conocer
PYMEs que, en algunos casos, han cambiado las nuevas solicitudes de patentes que se
sus líneas de fabricación para adaptarlas a la publican a nivel mundial relacionadas con la
apremiante necesidad de equipos de prevención, diagnóstico y tratamiento de las
protección, respiradores, etc.; sin olvidar a los enfermedades causadas por coronavirus en
centros de investigación y universidades que humanos.
están poniendo a disposición de la comunidad
sus equipos y capacidades.
Contenido
ANTIVIRALES Y OTROS VACUNAS DIAGNÓSTICO DISPOSITIVOS PARA EL
AGENTES PARA TRATAR TRATAMIENTO O CONTROL
PATOLOGÍAS ASOCIADAS A DE LA INFECCIÓN VÍRICA
LA ENFERMEDAD VIRAL
1
Si bien es cierto que aún no han sido acción antiviral, son aplicables al tratamiento
publicadas las primeras patentes referidas a la de las patologías asociadas a la infección vírica.
enfermedad ocasionada por el coronavirus
SARS-CoV-2, ya que desde que se realizan la Debe tenerse en cuenta que algunos de los
solicitudes de patente hasta su publicación han documentos son encuadrables en más de uno
de transcurrir los 18 meses que recogen todas de los apartados considerados. Tal es el caso,
las legislaciones nacionales e internacionales, por ejemplo, de aquellos que tienen por objeto
el conocimiento actual sobre otros beta- compuestos biológicos, como proteínas o
coronavirus que han causado epidemias en un ácidos nucleicos, con actividad antiviral que
pasado reciente (SARS-CoV y MERS-CoV) está también tienen aplicación en el desarrollo de
sirviendo como punto de partida para métodos de ensayo de identificación de otros
emprender nuevas actividades de agentes antivirales, y/o a la fabricación de
investigación y desarrollo para el tratamiento vacunas. Por ello, se ha adoptado el criterio de
de la COVID-19. Un reciente estudio publicado incluir el documento en todos los grupos
por ACS, accesible en ACS Cent. Sci. 2020, 6, pertinentes para facilitar la lectura. Para cada
315−331, recoge una revisión de patentes y patente se incluye su número de publicación,
literatura científica que tienen por objeto la con un enlace al documento completo
investigación y desarrollo de agentes publicado, su título, el país de origen y el
antivirales y vacunas para el tratamiento de solicitante.
enfermedades causadas por coronavirus. Como preámbulo de este primer número,
Otros editores de publicaciones científicas también se presenta un breve análisis
también han hecho accesible toda la estadístico que, con una cobertura temporal
documentación de que disponen, como The más amplia que el boletín, recoge los datos de
New England Journal of Medicine. familias de patentes publicadas en el periodo
En este número cero del Boletín, se incluyen 2004-2020, y que permite identificar la
todas las patentes publicadas desde 2018 evolución temporal de la tecnología y los
hasta marzo de 2020, distribuidas en cuatro países de origen de la misma, así como los
apartados: Antivirales y otros agentes para solicitantes más activos en el sector.
tratar patologías asociadas a la enfermedad Esperamos que la información aportada en
viral, Vacunas, Diagnóstico y Dispositivos para este Boletín de Vigilancia Tecnológica, sirva
el tratamiento o control de la infección vírica. para identificar tendencias tecnológicas y sus
El primer apartado, relativo a invenciones actores, así como para contribuir a la
sobre antivirales, es el que tiene una mayor utilización del conocimiento contenido en los
cobertura. Incluye documentos que tienen por documentos de patente como punto de
objeto agentes químicos, sean éstos no partida para emprender nuevas actividades de
biológicos o biomoléculas, con función investigación y desarrollo. Para suscribirse a
antiviral específica, así como vehículos para la este Boletín basta con cumplimentar este
administración al paciente de dichos agentes. formulario de suscripción.
Además, este primer bloque se refiere a
compuestos químicos o composiciones con La publicación trimestral del Boletín se
efecto antimicrobiano inespecífico útiles para complementa con una Alerta Tecnológica, de
la inactivación de las partículas virales. La publicación diaria que permitirá un
cobertura del grupo se extiende asimismo a seguimiento actualizado de las publicaciones a
herramientas moleculares y/o métodos útiles nivel mundial de nuevas solicitudes de patente
para el screening de nuevos agentes relacionadas con Coronavirus en humanos.
antivirales; y a productos que, sin tener una
2ANÁLISIS ESTADÍSTICO DE LAS SOLICITUDES DE
PATENTE PUBLICADAS EN EL PERIODO 2004-2020
El estudio se ha realizado empleando la herramienta GPI (Global Patent Index) de la Oficina Europea
de Patentes y ha consistido en un análisis de las familias de patentes publicadas desde 2004. Dicha
fecha se ha tomado como punto de partida para analizar la evolución de las solicitudes de patente
que se ha producido desde el primer brote de SARS ocurrido en 2002.
Como resultado del análisis, se han recuperado un total de 701 familias de patentes
(correspondientes a 2070 solicitudes), cuya distribución por año de publicación de la solicitud
representante de cada familia se muestra en la figura 1.
Fig. 1
La figura 2 recoge la distribución de las familias de patentes por país. Puede apreciarse que el 60%
de las patentes en el periodo considerado han tenido su origen en China (29,7 %), EEUU (19,1%) y
Corea del Sur (9,8%). A éstos han seguido, con un volumen considerablemente más bajo de
solicitudes, países como Japón, Países Bajos, Taiwan, Alemania, Canadá o Francia.
3Fig. 2
La figura 3 muestra cómo se distribuyen las solicitudes entre los 20 principales solicitantes
identificados en el estudio:
Fig. 3
Por último, en la figura 4 se ofrece una gráfica más detallada de la distribución del número de
patentes de esos 20 solicitantes por año de publicación de la solicitud.
4Fig. 4
5ANTIVIRALES Y OTROS AGENTES PARA TRATAR
PATOLOGÍAS ASOCIADAS A LA ENFERMEDAD
Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
ISOXAZOLE DERIVATIVES
WO2020040343 IL YANG PHARM CO LTD KR AND PREPARATION
PROCESS THEREOF
MONOCLONAL ANTIBODY
INDUSTRY ACADEMIC
AGAINST S PROTEIN OF
WO2020036403 COOPERATION FOUNDATION KR
MERS-CORONAVIRUS, AND
HALLYM UNIV
USE OF SAME
MODIFIED
OLIGONUCLEOTIDES FOR
WO2019240504 AM SCIENCES CO LTD KR
INHIBITION OF TARGET
GENE EXPRESSION
NEW CORONAVIRUS
VACCINE BASED ON
UNIV TSINGHUA CN CHIMPANZEE ADENOVIRUS
CN110616198
INST PASTEUR SHANGHAI CAS CN TYPE 68 AND MERS-COV
FULL LENGTH MEMBRANE
PROTEIN
CELL-STORED BARCODED
HUTCHINSON FRED CANCER US
DEEP MUTATIONAL
WO2020006494 RES
SCANNING LIBRARIES AND
UNIV WASHINGTON US
USES OF THE SAME
HBD2HUMAN BETA-
DEFENSIN 2 A
COMPOSITION FOR
PREVENTING OR TREATING
MERS-COV VIRUS
NAT UNIV CHONBUK IND
KR20190134578 KR COMPRISING HBD2 HUMAN
COOP FOUND
BETA-DEFENSIN 2 OR AN
FUSION PROTEIN
COMPRISING EPITOPE
PROTEIN OF MERS-COV
VIRUS AND THE HBD2
THIENOPYRIMIDINONES AS
US2019359629 FORMA THERAPEUTICS INC US UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS
COMPOUNDS FOR
DANA FARBER CANCER INST US
TREATING DENGUE VIRUS
WO2019222349 INC
INFECTIONS AND OTHER
HARVARD COLLEGE US
INFECTIONS
6Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
HUMAN ANTIBODIES TO
MIDDLE EAST RESPIRATORY
US2019351049 REGENERON PHARMA US SYNDROME -
CORONAVIRUS SPIKE
PROTEIN
NEW ANTIMICROBIAL
COMPOSITION AND
CN110302192 UNIV EAST CHINA NORMAL CN
PREPARATION METHOD
AND APPLICATION THEREOF
WHOLE PROTEIN GENE OF
MERS-COV
NUCLEOPROTEIN AND
KOREA RES INST BIOSCIENCE &
KR20190119391 KR VACCINE COMPOSITION
BIOTECHNOLOGY
FOR PREVENTING
INFECTION OF MERS-COV
COMPRISING THE SAME
APPLICATION OF MERS-COV
3CLPRO (MIDDLE EAST
RESPIRATORY SYNDROME
INST OF MILITARY MEDICINE
CORONAVIRUS 3C-LIKE
CN110257357 ACADEMY OF MILITARY CN
PROTEASE) AS
SCIENCES OF PLA
DEUBIQUITINATING
ENZYME AND INTERFERON
INHIBITOR
NUCLEIC ACID CONSTRUCT,
MEDICINAL COMPOSITION,
NAT UNIV CORPORATION
WO2019189827 JP ANTICANCER AGENT,
OKAYAMA UNIV
ANTIVIRAL AGENT AND
ANTIBACTERIAL AGENT
METHODS FOR THE USE OF
5'-ADENOSINE
US2019298752 INVIRSA INC US
DIPHOSPHATE RIBOSE
(ADPR)
ARYLNAPHTHALENE
COMPOUNDS AS
PURDUE RESEARCH
WO2019182947 US VACUOLAR-ATPASE
FOUNDATION
INHIBITORS AND THE USE
THEREOF
CHIMERIC FC RECEPTOR
LIVERPOOL SCHOOL OF
WO2019175605 GB BINDING PROTEINS AND
TROPICAL MEDICINE
USES THEREOF
ANTIVIRAL COMPOUNDS
WO2019175436 UNIV DEGLI STUDI DI SIENA IT
AND USE THEREOF
7Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
4'-HALOGEN CONTAINING
NUCLEOTIDE AND
NUCLEOSIDE THERAPEUTIC
WO2019173602 UNIV EMORY US COMPOSITIONS AND USES
RELATED THERETO
PREPARATION AND USES OF
NOVEL MICHAEL
CN110105348 UNIV NANKAI CN RECEPTOR-BASED
ENTEROVIRUS 71 TYPE
INHIBITOR
MERS-COV FUSION
INST OF MILITARY MEDICINE
INHIBITOR
CN110128510 ACADEMY OF MILITARY CN
SCIENCES OF PLA
METHODS FOR TREATING
ARENAVIRIDAE AND
US2019255085 GILEAD SCIENCES INC US
CORONAVIRIDAE VIRUS
INFECTIONS
NSP13 COMPOUNDS THAT
UNIV KOOKMIN IND ACAD INHIBIT MERS
KR20190092776 KR
COOP FOUND CORONAVIRUS HELICASE
NSP13 AND USES THEREOF
GLUCOSAMINE AND
INST OF MILITARY MEDICINE APPLICATION OF
CN109771432 ACADEMY OF MILITARY CN DERIVATIVE OF
SCIENCES OF PLA GLUCOSAMINE AS
ANTIVIRAL DRUG
S1 MONOCLONAL
ANTIBODIES OF
KOREA CENTER FOR DISEASE
KR102007161 KR SPECIFICALLY BINDING TO
CONTROL AND PREVENTION
SPIKE S1 PROTEIN OF MERS-
COV
BINDING MOLECULE
HAVING NEUTRALIZING
WO2019151632 CELLTRION INC KR ACTIVITY AGAINST MIDDLE
EAST RESPIRATORY
SYNDROME-CORONAVIRUS
METHOD FOR DETECTING
CN109988865 UNIV XIAMEN CN
RESPIRATORY VIRUSES
MERS-COV INFECTION
ACAD OF MILITARY MEDICAL
WO2019136824 CN INHIBITING POLYPEPTIDE
SCIENCES
8Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
RECOMBINANT VECTOR OF
MERS-COV EXPRESSING
KOREA CENTER FOR DISEASE KR
FLUORESCENCE PROTEIN
KR102005685 CONTROL AND PREVENTION
DERIVED FROM KOREAN
UNIV YONSEI IACF KR
MERS-COV AND METHOD
OF PREPARING THE SAME
PEPTIDES HAVING
PROTEASE ACTIVITY FOR
WO2019135003 ENZYMATICA AB SE USE IN THE TREATMENT OR
PREVENTION OF
CORONAVIRUS INFECTION
HBD2HUMAN BETA-
DEFENSIN 2 A
COMPOSITION FOR
PREVENTING OR TREATING
MERS-COV VIRUS
NAT UNIV CHONBUK IND
KR20190070629 KR COMPRISING HBD2 HUMAN
COOP FOUND
BETA-DEFENSIN 2 OR AN
FUSION PROTEIN
COMPRISING EPITOPE
PROTEIN OF MERS-COV
VIRUS AND THE HBD2L
MONOCLONAL ANTIBODY
MERS-4V2 AND ENCODING
CN109666070 UNIV TSINGHUA CN
GENE AND APPLICATION
THEREOF
N4-HYDROXYCYTIDINE AND
DERIVATIVES AND ANTI-
WO2019113462 UNIV EMORY US
VIRAL USES RELATED
THERETO
GSK-3Β INHIBITORS AND
WO2019108877 UNIV HAWAII US USE THEREOF IN METHODS
OF TREATMENT
ANTIVIRUS-STERILIZING
JP2019077681 NBC MESHTEC INC JP
DISINFECTANT
AURIGENE DISCOVERY TECH IN CONJOINT THERAPIES FOR
WO2019087092
LIMITED CURIS INC US IMMUNOMODULATION
COMPOSITIONS AND
AVALON FLAVIVIRAL CN
METHODS FOR BROAD-
THERAPEUTICS HK LTD
WO2019079339 SPECTRUM ANTIVIRAL
VERSITECH LTD CN
THERAPY
LAU JOHNSON YIU NAM US
9Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
METHOD FOR HIGH-
THROUGHPUT SCREENING
OF NEUTRALIZING
WO2019079671 ACAD SINICA YANG AN SUEI US ANTIBODIES,
NEUTRALIZING ANTIBODIES
PRODUCED THEREFROM,
AND USES THEREOF
USE OF ASC AND ASC-CM
UNIV INDIANA RES & TECH US
TO TREAT ARDS, SARS, AND
US2019117702 CORP
MERS
US VETERANS AFFAIRS US
NOVEL PLATFORMS FOR
CO-STIMULATION, NOVEL
CAR DESIGNS AND OTHER
WO2019067805 UNIV SOUTHERN CALIFORNIA US
ENHANCEMENTS FOR
ADOPTIVE CELLULAR
THERAPY
DNA ANTIBODY
CONSTRUCTS FOR USE
WEINER DAVID US
WO2019067671 AGAINST MIDDLE EAST
SMITH TREVOR RF US
RESPIRATORY SYNDROME
CORONAVIRUS
ALPHA-KETOAMIDE
US2019085024 PHELIX THERAPEUTICS US INHIBITORS OF CYSTEINE
PROTEASES
MICROBICIDAL
UNIV LOUISVILLE RES FOUND COMPOSITIONS AND
US2019083569 US
INC METHODS FOR TREATMENT
OF VIRAL INFECTIONS
AROMATIC THIOETHER
COMPOUNDS AS WELL AS
CN109111405 UNIV NANKAI CN PESTICIDES CONTAINING
SAME AND MEDICAL
APPLICATION THEREOF
PSEUDO MERS-COV VIRUS
NAT INSTITUTES FOR FOOD OF INFECTED ANIMAL, AND
CN109055427 CN
AND DRUG CONTROL PREPARATION METHOD
AND APPLICATION THEREOF
FLEX-NUCLEOSIDE
ANALOGUES, NOVEL
WO2019027501 UNIV MARYLAND US THERAPEUTICS AGAINST
FILOVIRUSES AND
FLAVIVIRUSES
10Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
HUMAN DPP4 GENE
KNOCK-IN MOUSE MODEL
NAT INSTITUTES FOR FOOD
CN109022489 CN AND PRODUCTION
AND DRUG CONTROL
METHOD AND USE
THEREOF
PHARMACEUTICAL
COMPOSITION FOR
UNIV ULSAN FOUND IND COOP KR
WO2019022357 PREVENTING OR TREATING
ASAN FOUND KR
MIDDLE EAST RESPIRATORY
SYNDROME
TRACKING AND
MANIPULATING CELLULAR
US2019040370 UNIV CALIFORNIA US RNA VIA NUCLEAR
DELIVERY OF CRISPR/CAS9
SODIUM SULFIDE ENTERIC-
YANG LIYING
COATED TABLET AND
CN108938589 YANG YUN CN
PREPARATION METHOD
SHI YUYUAN
AND INDICATIONS THEREOF
UNIV NORTH CAROLINA US COMPOSITIONS AND
US2019023769 CHAPEL HILL METHODS FOR INHIBITING
UNIV JOHNS HOPKINS US PATHOGEN INFECTION
BROAD INST INC US
MASSACHUSETTS INST US CRISPR SYSTEM BASED
WO2019010422
TECHNOLOGY ANTIVIRAL THERAPY
HARVARD COLLEGE US
JAPAN HEALTH SCIENCES MONOCLONAL ANTIBODIES
JP2018203632 JP
FOUND AND ASSAY KITS
APPLICATION OF
INST FOR VIRAL DISEASE
MONENSIN IN
CONTROL AND PREVENTION
CN108721271 CN PREPARATION OF BROAD-
CHINESE CENTER FOR DISEASE
SPECTRUM ANTI-
CONTROL AND PREVENTION
CORONAVIRUS DRUGS
PEPTIDES AND USES
WO2018217075 VIRAMATIX SDN BHD MY THEREFOR AS ANTIVIRAL
AGENTS
APPLICATION OF PP
INST FOR VIRAL DISEASE (PYRVINIUM PAMOATE) IN
CONTROL AND PREVENTION PREPARATION OF BROAD-
CN108721292 CN
CHINESE CENTER FOR DISEASE SPECTRUM ANTI-COV
CONTROL AND PREVENTION (CORONAVIRUS) DRUG
11Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
ANTI-VIRUS POLYPEPTIDE
MILITARY MEDICAL RES
AS WELL AS
INSTITUTE OF THE CHINESE
CN108659105 CN PHARMACEUTICAL
ACADEMY OF MILITARY
COMPOSITION AND
SCIENCES
APPLICATION THEREOF
UNIV DE COIMBRA PT
FACULDADE DE FARMACIA DA PT
UNIV DE LISBOA NOVEL SPIRO-LACTAM
WO2018207165 EGAS MONIZ COOP DE ENSINO PT COMPOUNDS, PROCESS
SUPERIOR CRL AND USES THEREOF
INST DE MEDICINA PT
MOLECULAR
CRYSTALLINE FORMS OF (S)
2 ETHYLBUTYL 2 (((S)
(((2R,3S,4R,5R) 5 (4
AMINOPYRROLO[2,1-F]
[1,2,4]TRIAZIN-7-YL)-5-
WO2018204198 GILEAD SCIENCES INC US CYANO-3,4-
DIHYDROXYTETRAHYDROFU
RAN-2
YL)METHOXY)(PHENOXY)
PHOSPHORYL)AMINO)PROP
ANOATE
INST FOR VIRAL DISEASE APPLICATION OF EMETINE
CONTROL AND PREVENTION IN PREPARATION OF BROAD
CN108721293 CN
CHINESE CENTER FOR DISEASE SPECTRUM ANTI-
CONTROL AND PREVENTION CORONAVIRUS DRUG
MONOCLONAL ANTIBODY
AGAINST SPIKE PROTEIN OF
KOREA CENTER FOR DISEASE
KR101895228 KR MIDDLE EAST RESPIRATORY
CONTROL AND PREVENTION
SYNDROME CORONAVIRUS
AND USES THEROF
APPLICATION OF LYCORINE
INST FOR VIRAL DISEASE
IN PREPARATION OF
CONTROL AND PREVENTION
CN108478571 CN BROAD-SPECTRUM ANTI-
CHINESE CENTER FOR DISEASE
CORONAVIRUS DRUGS
CONTROL AND PREVENTION
12Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
COMPOSITIONS FOR
REPROGRAMMING CELLS
CENTRO DE NEUROCIENCIAS E INTO DENDRITIC CELLS OR
WO2018185709 PT
BIOLOGIA CELULAR ANTIGEN PRESENTING
CELLS, METHODS AND USES
THEREOF
QUINOLINONE COMPOUND
WO2018181892 UNIV NAGASAKI JP
AND ANTI-RNA VIRUS DRUG
COMPOUND FOR TREATING
KOREA RES INST CHEMICAL
WO2018174442 KR DISEASES CAUSED BY
TECH
CORONAVIRUS INFECTION
APPLICATION OF
MYCOPHENOLIC ACID AND
INST FOR VIRAL DISEASE
ITS DERIVATIVE
CONTROL AND PREVENTION
CN108478562 CN MYCOPHENOLATE MOFETIL
CHINESE CENTER FOR DISEASE
IN PREPARATION OF
CONTROL AND PREVENTION
BROAD-SPECTRUM ANTI-
CORONAVIRUS DRUGS
ACAD OF MILITARY SCIENCES
MERS-COV INFECTION
CN108395471 PLA CHINA ACAD OF MILITARY CN
INHIBITION POLYPEPTIDE
MEDICAL SCIENCES
CONTROL OF TOTAL
AFUCOSYLATED
WO2018170099 AMGEN INC US GLYCOFORMS OF
ANTIBODIES PRODUCED IN
CELL CULTURE
ACADEMISCH ZIEKENHUIS NL
LEIDEN
VIRAL POLYPEPTIDE
WO2018164573 GOVERNING COUNCIL UNIV CA
INHIBITORS
TORONTO
UNIV OF MANITOBA CA
MATRIPTASE INHIBITORS
WO2018112648 NEOMED INST CA
AND USES THEREOF
THERAPEUTIC INHIBITORS
WO2018134265 FORREST MICHAEL DAVID GB OF THE REVERSE MODE OF
ATP SYNTHASE
SARSMERS COMPOSITIONS
FOR ANTI-AVIAN
INFLUENZA VIRUS SARS
KR20180079136 GREEN T IND CO LTD KR
MERS CORONAVIRUS BY
MICRO ENCAPSULIZED
NATURAL HERBS
13Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
IMPROVED METHODS FOR
ENHANCING ANTIBODY
PRODUCTIVITY IN
MAMMALIAN CELL
CULTURE AND MINIMIZING
SERUM INSTITUTE OF INDIA
WO2018116198 IN AGGREGATION DURING
PRIVATE LTD
DOWNSTREAM,
FORMULATION PROCESSES
AND STABLE ANTIBODY
FORMULATIONS OBTAINED
THEREOF
ANTIVIRAL COMPOSITIONS
UNIV CLAUDE BERNARD LYON FR
FOR THE TREATMENT OF
WO2018073549 INST NAT SANTE RECH MED FR
INFECTIONS LINKED TO
CENTRE NAT RECH SCIENT FR
CORONAVIRUSES
LIPIDATED IMMUNE
RESPONSE MODIFIER
3M INNOVATIVE PROPERTIES COMPOUND
AU2018202168 AU
CO COMPOSITIONS,
FORMULATIONS, AND
METHODS
FGFR REGULATON FOR THE
EP3308786 ETH ZUERICH CH TREATMENT OF VIRAL
INFECTIONS
COMPOUNDS THAT INHIBIT
GLAXOSMITHKLINE IP NO 2 3C AND 3CL PROTEASES
WO2018042343 GB
LTD AND METHODS OF USE
THEREOF
GRL INC US
KISELEV OLEG I RU
RUSINOV VLADIMIR RU
ULOMSKY EVGENY RU
SMALL MOLECULES HAVING
MEDVEDEVA NATALIA RU
WO2018035509 ANTIVIRAL PROPERTIES
SAPOZHNIKOVA IRINA RU
CHARUSHIN VALERY RU
CHUPAKHIN OLEG RU
DANILENKO DARIA RU
DEEVA ELLA RU
14Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
A ANTIBODY ABLE TO
NEUTRALIZE MIDDLE EAST
KR101828794 CELLTRION INC KR
RESPIRATORY SYNDROME
CORONAVIRUS
JP2018020989 UBE INDUSTRIES JP UREA COMPOUND
KANSAS STATE UNIV US PROTEASE TRANSITION
WO2018023054 RESEARCH FOUNDATION STATE INHIBITOR
WICHITA STATE UNIV US PRODRUGS
ANTIMICROBIAL
GEOPOLYMER
SEO DONG-KYUN US
WO2018013830 COMPOSITIONS
HAYDEL SHELLEY US
ZHU ZHIFANG US TRYPTOPHAN IS A PRO-
US2018015072 ZHANG JUN CN DRUG FOR INFECTIOUS
LI JINMING CN DISEASES AND CANCERS
KR20170136731 AN SANG JUN KR
ANTI-ENTEROVIRAL
71(EV71) 4-
IMINOOXAZOLIDINE-2-
KETONE COMPOUND AS
WELL AS PREPARATION
CN107459511 UNIV NANKAI CN
METHOD AND APPLICATION
OF ANTI-ENTEROVIRAL
71(EV71) 4-
IMINOOXAZOLIDINE-2-
KETONE COMPOUND
SMALL MOLECULE
KANSAS STATE UNIV US THERAPEUTIC INHIBITORS
WO2017222935 RESEARCH FOUNDATION AGAINST PICORNAVIRUSES,
WICHITA STATE UNIV US CALICIVIRUSES, AND
CORONAVIRUSES
METHODS FOR INHIBITING
WO2020024060 UNIV MCMASTER CA
MICROBE GROWTH
MEDICINAL SALT FOR
JIANGSU HENGRUI MEDICINE CN PYRAZOLO-HETEROARYL
CO DERIVATIVE AND CRYSTAL
CN110526917
SHANGHAI HENGRUI CN FORM AND PREPARATION
PHARMACEUTICAL CO LTD METHOD OF MEDICINAL
SALT
METHODS OF
ADMINISTERING
US2020038387 INTERMUNE INC US
PIRFENIDONE THERAPY
15Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
WET WIPE FOR
DISINFECTING AND
CN110464737 ZHU JIANG CN STERILIZING AS WELL AS
PREPARATION METHOD OF
WET WIPE
CRYSTAL FORM OF
JIANGSU HENGRUI MEDICINE CN
HYDROCHLORIDE OF
CO
WO2019223773 PYRAZOLOHETEROARYL
SHANGHAI HENGRUI CN
DERIVATIVE AND
PHARMACEUTICAL CO LTD
PREPARATION METHOD
COMPOSITION FOR
TREATING VIRAL DISEASES
ROZIEV RAKHIMDZHAN
WO2019203697 RU (VARIANTS)
AKHMETDZHANOVICH
CYANO-PYRROLO-
JIANGSU HENGRUI MEDICINE CN HETEROARYL DERIVATIVE,
CO PREPARATION METHOD
CN110317202
SHANGHAI HENGRUI CN THEREOF AND APPLICATION
PHARMACEUTICAL CO LTD OF DERIVATIVE TO
MEDICINE
COMPOSITIONS AND
WO2019195179 CAPIENDA BIOTECH LLC US METHODS FOR TREATING
INFLAMMATORY DISEASES
JIANGSU HENGRUI MEDICINE CN BENZOAZA * DERIVATIVE,
CO PREPARATION METHOD
CN109956903
SHANGHAI HENGRUI CN AND APPLICATION THEREOF
PHARMACEUTICAL CO LTD TO MEDICINE
APPLICATIONS OF
MONOMER SILVER ATOM
AS ANTIBACTERIAL
CN110089523 AI MINGNAN CN
MATERIAL IN PREPARATION
OF ANTIBACTERIAL
PRODUCTS
JIANGSU HENGRUI MEDICINE CN BENZOAZEPINE DERIVATIVE
CO AS WELL AS PREPARATION
CN109694351
SHANGHAI HENGRUI CN METHOD AND MEDICAL
PHARMACEUTICAL CO LTD APPLICATION THEREOF
EPHEDRA HOMO
POLYSACCHARIDE ESP-B4
CN109678982 WANG QIUHONG CN AS WELL AS PREPARATION
METHOD AND APPLICATION
THEREOF
16Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
COMPOSITIONS AND
METHODS OF
SHANGHAI YAO YUAN MODULATING THE
WO2019080898 CN
BIOTECHNOLOGY CO LTD IMMUNE RESPONSE BY
ACTIVATING ALPHA
PROTEIN KINASE 1
COMPOSITIONS, SYSTEMS,
WO2019094969 SYNTHETIC GENOMICS INC US KITS, AND METHODS FOR
MODIFYING RNA
APPLICATION OF TIM-3
INTERACTION WITH NF90
IN PRODUCTS FOR THE
CN109266731 DOU SHUAIJIE CN
PREVENTION OR
TREATMENT OF VIRAL
INFECTION
CONDENSED HETEROARYL
JIANGSU HENGRUI MEDICINE CN DERIVATIVES,
CO PREPARATION METHOD
WO2019057158
SHANGHAI HENGRUI CN THEREFOR, AND
PHARMACEUTICAL CO LTD APPLICATION THEREOF IN
MEDICINES
2,2-DIMETHYL-1,2-
GUOKE WEISI BEIJING DIOXOLAME DERIVATIVE,
CN109134419 CN
MEDICAMENT RES CO LTD PREPARATION METHOD
AND APPLICATION THEREOF
WO2019046316 ACURASTEM INC US PIKFYVE KINASE INHIBITORS
PURINONE DERIVATIVE
SHANGHAI HENGRUI CN
AND PREPARATION
PHARMACEUTICAL CO LTD
CN108948016 METHOD THEREOF AND
JIANGSU HENGRUI MEDICINE CN
APPLICATION THEREOF IN
CO
MEDICINES
S2 A METHOD FOR
UNIV INDUSTRY KR
PRODUCING MERS
COOPERATION GROUP KYUNG
KR20190000009 ANTIGEN USING
HEE UNIV
DROSOPHILA
BOREDA BIOTECH KR
MELANOGASTOR S2
CONDENSED RING BASED
KETONE DERIVATIVES,
PREPARATION METHOD
JIANGSU HENGRUI MEDICINE CN
THEREOF AND APPLICATION
CO
CN108794486 OF DERIVATIVES IN
SHANGHAI HENGRUI CN
MEDICINE
PHARMACEUTICAL CO LTD
17Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
APPLICATION OF
ACAMPROSATE CALCIUM IN
TIANJIN INT JOINT ACADEMY RESISTANCE TO SARS
CN108785293 CN
OF BIOMEDICINE (SEVERE ACUTE
RESPIRATORY SYNDROME)
CORONAVIRUS INFECTION
PANICINOTAM ANALOG
AND PREPARATION
CN108690024 OCEAN UNIV CHINA CN
METHOD AND USE
THEREOF
NITROGEN-CONTAINING
BICYCLIC COMPOUND,
CN108658855 OCEAN UNIV CHINA CN
PREPARATION METHOD
AND USES THEREOF
APPLICATIONS OF LACTAM-
CN108670970 OCEAN UNIV CHINA CN BASED COMPOUND IN
DRUGS
COMPOUNDS FOR
DANA FARBER CANCER INST US
TREATING DENGUE VIRUS
WO2018213365 INC
INFECTION AND OTHER
HARVARD COLLEGE US
VIRAL INFECTIONS
COLLEGE OF MEDICINE KR
POCHON CHA UNIV INDUSTRY
METHODS FOR TREATING
ACADEMIC COOPERATION
PULMONARY FIBROSIS
US2018338948 FOUNDATION
USING CHROMENONE
UNIV EWHA IND KR
DERIVATIVES
COLLABORATION
UNIV YONSEI IACF KR
CARBONYL-CONTAINING
AMINE COMPOUND AS
CN108623587 OCEAN UNIV CHINA CN WELL AS PREPARATION
METHOD AND APPLICATION
THEREOF
TETRACYCLIC LACTAM
COMPOUND, PREPARATION
CN108623589 OCEAN UNIV CHINA CN METHOD AND APPLICATION
THEREOF
18Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
A PROCESS FOR
MANUFACTURING POROUS
SILICA PARTICLES LOADED
WITH AT LEAST ONE
WO2018202818 NANOLOGICA AB SE BIOACTIVE COMPOUND
ADAPTED FOR LUNG,
NASAL, SUBLINGUAL
AND/OR PHARYNGEAL
DELIVERY
LACTAM COMPOUND, AND
PREPARATION METHOD
WO2018177296 OCEAN UNIV CHINA CN
THEREFOR AND USE
THEREOF
SUBSTITUTED LACTAM
COMPOUND, AND
WO2018177297 OCEAN UNIV CHINA CN PREPARATION METHOD
THEREFOR AND USE
THEREOF
METHODS AND
COMPOSITIONS FOR
PRODUCTION OF
US2018280461 PHARMA GREEN LLC US RECOMBINANT
PHARMACEUTICAL
PROTEINS IN MEDICINAL
PLANTS
COMPOSITIONS AND
METHODS FOR
DANA FARBER CANCER INST
WO2018145075 US AUGMENTING ANTIBODY
INC
MEDIATED RECEPTOR
SIGNALING
HETEROAROTHIADIAZIDE-
JIANGSU HENGRUI MEDICINE CN 2,2-DIOXIDE DERIVATIVE,
CO AND PREPARATION
WO2018137614
SHANGHAI HENGRUI CN METHOD THEREFOR AND
PHARMACEUTICAL CO LTD APPLICATION THEREOF IN
MEDICAMENT
FUTURE MEDICINE CO LTD KR CARBOCYCLIC NUCLEOSIDE
WO2018131950 SEOUL NAT UNIV R&DB KR DERIVATIVE AND ANTIVIRAL
FOUNDATION AGENT COMPRISING SAME
FREEZING PREPARATION
METHOD AND APPLICATION
OF BIOACTIVE
CN107875984 WUHAN INST TECHNOLOGY CN
SUBSTANCE/WATER-
SOLUBLE DRUG
MICROCAPSULE
19Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
PREVENTATIVE MANNOSE
THERAPY AND TREATMENT
HOWARD UNIV US
OF VIRAL INFECTIONS
WO2018102722
USING MANNOSE-
CHANDRAN PREETHI US
CONTAINING
COMPOSITIONS
NITROGEN-CONTAINING
HETEROCYCLIC
LIVO SHANGHAI COMPOUND, PREPARATION
WO2018086593 CN
PHARMACEUTICAL CO LTD METHOD, INTERMEDIATE,
PHARMACEUTICAL
COMPOSITION AND USE
METHODS FOR TREATING
PULMONARY DISEASE
WO2018053029 PROTHERA BIOLOGICS INC US
USING INTER-ALPHA
INHIBITOR PROTEINS
UNIV UTAH RES FOUND US
IN SITU GELLING
GHANDAHARI HAMID US
COMPOSITIONS FOR THE
OOTTAMASATHIEN SIAM US
TREATMENT OR
WO2018053111 JESEN MARK MARTIN US
PREVENTION OF
CAPPELLO JOSEPH US
INFLAMMATION AND
JAI WANJIAN US
TISSUE DAMAGE
PRESTWICH GLENN D US
TOLL LIKE RECEPTOR
US2018065938 GILEAD SCIENCES INC US
MODULATOR COMPOUNDS
METHODS OF
US2018064695 INTERMUNE INC US ADMINISTERING
PIRFENIDONE THERAPY
METHODS FOR
QUANTITATING INDIVIDUAL
WO2018034885 REGENERON PHARMA US
ANTIBODIES FROM A
MIXTURE
GENMAB AS DK MULTISPECIFIC ANTIBODIES
WO2018011421
BIONTECH AG DE AGAINST CD40 AND CD137
PHENYL DILACTONE
COMPOUNDS AND USES IN
CN109912613 UNIV FUDAN CN
PREPARATION OF ANTI-
COMPLEMENT DRUGS
20VACUNAS
Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
EXPRESSION VECTOR
SYSTEM FOR PREPARING
RECOMBINANT SELF-
KR102076917 UNIV YONSEI IACF KR ASSEMBLED
NANOPARTICLES AND
METHOD OF USING THE
SAME
FC- POLYPEPIDE FOR
NAT UNIV CHONBUK IND KR
DELIVERY OF ANTIGEN FC-
COOP FOUND
KR20200008288 FUSION PROTEIN
ST GEORGES UNIV OF GB
COMPRISING THEREOF
LONDON
AND USE THEREOF
IMMUNOBIOLOGICAL
FEDERALNOE
AGENT AND A METHOD
GOSUDARSTVENNOE
FOR USE THEREOF FOR
BYUDZHETNOE
INDUCING SPECIFIC
RU2709659 UCHREZHDENIE RU
IMMUNITY TO THE
NATSIONALNYJ
MIDDLE EASTERN
ISSLEDOVATELSKIJ TSENTR
RESPIRATORY SYNDROME
EPIDEMIOLOG
VIRUS (VERSIONS)
NEW CORONAVIRUS
VACCINE BASED ON
UNIV TSINGHUA CN CHIMPANZEE
CN110616198
INST PASTEUR SHANGHAI CAS CN ADENOVIRUS TYPE 68 AND
MERS-COV FULL LENGTH
MEMBRANE PROTEIN
HBD2HUMAN BETA-
DEFENSIN 2 A
COMPOSITION FOR
PREVENTING OR
TREATING MERS-COV
NAT UNIV CHONBUK IND VIRUS COMPRISING HBD2
KR20190134578 KR
COOP FOUND HUMAN BETA-DEFENSIN 2
OR AN FUSION PROTEIN
COMPRISING EPITOPE
PROTEIN OF MERS-COV
VIRUS AND THE HBD2
21Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
WHOLE PROTEIN GENE OF
MERS-COV
NUCLEOPROTEIN AND
KOREA RES INST BIOSCIENCE
KR20190119391 KR VACCINE COMPOSITION
& BIOTECHNOLOGY
FOR PREVENTING
INFECTION OF MERS-COV
COMPRISING THE SAME
PHARMACEUTICAL
SECR DEFENCE GB
COMPOSITIONS AND
WO2019202285 PROXIMA CONCEPTS LTD GB
ASSOCIATED KITS AND
THE UNIV OF STRATHCLYDE GB
USES
BURKHOLDERIA
THE ADMINISTRATORS OF
PSEUDOMALLEI COMPLEX
WO2019199955 THE TULANE EDUCATIONAL US
OUTER MEMBRANE
FUND
VESICLES AS ADJUVANTS
CHIMERIC FC RECEPTOR
LIVERPOOL SCHOOL OF
WO2019175605 GB BINDING PROTEINS AND
TROPICAL MEDICINE
USES THEREOF
RECOMBINANT VECTOR
OF MERS-COV
KOREA CENTER FOR DISEASE KR EXPRESSING
KR102005685 CONTROL AND PREVENTION FLUORESCENCE PROTEIN
UNIV YONSEI IACF KR DERIVED FROM KOREAN
MERS-COV AND METHOD
OF PREPARING THE SAME
BACULOVIRUS-BASED
UNIV KONKUK IND COOP KR GENE CARRIER
WO2019143180 CORP COMPRISING INFLUENZA-
KR BIOTECH CO LTD KR DERIVED CELL-
PENETRATING PEPTIDE
NON-VIRAL PRODUCTION
WO2019118806 SOLID BIOSCIENCES INC US
AND DELIVERY OF GENES
PSEUDO MERS-COV VIRUS
OF INFECTED ANIMAL,
NAT INSTITUTES FOR FOOD
CN109055427 CN AND PREPARATION
AND DRUG CONTROL
METHOD AND
APPLICATION THEREOF
HUMAN DPP4 GENE
KNOCK-IN MOUSE MODEL
NAT INSTITUTES FOR FOOD
CN109022489 CN AND PRODUCTION
AND DRUG CONTROL
METHOD AND USE
THEREOF
ATTENUATED VIRUSES
UNIV NEW YORK STATE RES USEFUL FOR VACCINES
EP3431099 US
FOUND
22Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
VACCINE COMPOSITION
EP3431101 EUROCINE VACCINES AB SE
FOR NAIVE SUBJECTS
COMPOSITIONS
COMPRISING AN RNA
POLYMERASE INHIBITOR
WO2019014247 GILEAD SCIENCES INC US
AND CYCLODEXTRIN FOR
TREATING VIRAL
INFECTIONS
BROAD INST INC US
MASSACHUSETTS INST US CRISPR SYSTEM BASED
WO2019010422
TECHNOLOGY ANTIVIRAL THERAPY
HARVARD COLLEGE US
PHENOTYPICALLY WILD-
SHACKELTON LAURA US
WO2018222983 TYPE AND GENETICALLY
KERNER MATTHEW US
ATTENUATED VIRUSES
GENETICALLY
SHACKELTON LAURA US
WO2018222986 ATTENUATED NUCLEIC
KERNER MATTHEW US
ACID VACCINE
COMPOSITIONS AND
UNIV OXFORD INNOVATION
WO2018215766 GB METHODS FOR INDUCING
LTD
AN IMMUNE RESPONSE
REGENERON PHARMA US GENETICALLY MODIFIED
UNIV YALE US NON-HUMAN ANIMALS
US2018295820
INSTITUTE FOR RES IN CH AND METHODS OF USE
BIOMEDICINE IRB THEREOF
SELF-ASSEMBLING
PROTEIN NANOPARTICLES
WO2018172447 ALPHA O PEPTIDES AG CH
WITH BUILT-IN SIX-HELIX
BUNDLE PROTEINS
ZOONOTIC DISEASE RNA
WO2018170347 MODERNATX INC US
VACCINES
CORONAVIRUSES,
VACCINES COMPRISING
WO2018160977 LOYOLA UNIV CHICAGO US
THE SAME, AND METHODS
FOR PREVENTING DISEASE
ENEA AGENZIA NAZ PER LE IT
NUOVE TECNOLOGIE PLANT PROTEIN SIGNAL
WO2018122885 LENERGIA E LO SVILUPPO SEQUENCE AS ADJUVANT
ECONOMICO SOSTENIBILE IN DNA VACCINES
ST FISIOTERAPICI OSPITALIERI IT
MERS CORONAVIRUS
VACCINE
WO2018115527 CUREVAC AG DE
23Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
MIDDLE EAST
RESPIRATORY SYNDROME
CORONAVIRUS S PROTEIN
WO2018097603 SK CHEMICALS CO LTD KR IMMUNOGENIC
COMPOSITION AND
METHOD FOR PREPARING
SAME
IMMUNOGENIC
COMPOSITIONS
WO2018096089 THE UNIV OF BATH GB
COMPRISING SBI PROTEIN
AND USES THEREOF
IMMUNOGENIC
NEW YORK BLOOD CENTER
WO2018094241 US COMPOSITION FOR MERS
INC
CORONAVIRUS INFECTION
US HEALTH US PREFUSION CORONAVIRUS
WO2018081318 DARTMOUTH COLLEGE US SPIKE PROTEINS AND
SCRIPPS RESEARCH INST US THEIR USE
IMMUNE RESPONSE
REGULATORY SUBSTANCE
WO2018080252 EYEGENE INC KR AND VACCINE
COMPOSITION
CONTAINING SAME
LIPIDATED IMMUNE
RESPONSE MODIFIER
3M INNOVATIVE PROPERTIES COMPOUND
AU2018202168 AU
CO COMPOSITIONS,
FORMULATIONS, AND
METHODS
METHODS AND
COMPOSITIONS FOR
UNIV WASHINGTON
ACTIVATION OF INNATE
US2018104325 THROUGH ITS CENTER FOR US
IMMUNE RESPONSES
COMMERCIALIZATION
THROUGH RIG-I LIKE
RECEPTOR SIGNALING
IMMUNOGENIC
COMPOSITIONS AND
METHODS RELATING
WO2018017443 HARVARD COLLEGE US THERETO
SELF-ASSEMBLING INSECT
FERRITIN NANOPARTICLES
FOR DISPLAY OF CO-
WO2018005558 US HEALTH US
ASSEMBLED TRIMERIC
ANTIGENS
24Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
IMMUNOMODULATORY
COMPOSITIONS,
NANTBIO INC US PROCESSES FOR MAKING
WO2018089637
NANT HOLDINGS IP LLC US THE SAME, AND METHODS
FOR INHIBITING CYTOKINE
STORMS
VACCINE COMPOSITION
COMPRISING HEPATITIS B
WO2018095327 HUANG LIMIN CN
VIRUS-LIKE PARTICLES AS
ADJUVANT
FC VARIANT
DANA FARBER CANCER INST COMPOSITIONS AND
WO2019183362 US
INC METHODS OF USE
THEREOF
SELF-ASSSEMBLING
WO2019169120 UNIV WASHINGTON US NANOSTRUCTURE
VACCINES
BIONTECH RNA DE
PHARMACEUTICALS GMBH
TRON TRANSLATIONALE DE FORMULATION FOR
WO2019137999
ONKOLOGIE AN DER UNIV ADMINISTRATION OF RNA
DER JOHANNES GUTENBERG
UNIV MAINZ GGMBH
COMPOSITIONS AND
METHODS OF
SHANGHAI YAO YUAN MODULATING THE
WO2019080898 CN
BIOTECHNOLOGY CO LTD IMMUNE RESPONSE BY
ACTIVATING ALPHA
PROTEIN KINASE 1
APPLICATION OF TIM-3
INTERACTION WITH NF90
IN PRODUCTS FOR THE
CN109266731 DOU SHUAIJIE CN
PREVENTION OR
TREATMENT OF VIRAL
INFECTION
WO2019020493 MEDI IMMUNE LTD GB VACCINE COMPOSITIONS
VACCINE COMPOSITION
GB2564901 MEDI IMMUNE LTD GB
S2 A METHOD FOR
UNIV INDUSTRY KR PRODUCING MERS
COOPERATION GROUP ANTIGEN USING
KR20190000009
KYUNG HEE UNIV DROSOPHILA
BOREDA BIOTECH KR MELANOGASTOR S2
25Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
FREEZING PREPARATION
METHOD AND
APPLICATION OF
CN107875984 WUHAN INST TECHNOLOGY CN BIOACTIVE
SUBSTANCE/WATER-
SOLUBLE DRUG
MICROCAPSULE
IMMUNITY ENHANCING
COMPOSITION INCLUDING
IMMUNE RESPONSE
WO2018080253 EYEGENE INC KR
REGULATOR AND
CATIONIC LIPOSOME, AND
USE OF SAME
BIONTECH RNA DE
PHARMACEUTICALS GMBH
TRON TRANSLATIONALE DE
FORMULATION FOR
WO2018011406 ONKOLOGIE AN DER
ADMINISTRATION OF RNA
UNIVERSITÄTSMEDIZIN DER
JOHANNES GUTENBERG-
UNIVERSITÄT MAINZ
CELL-STORED BARCODED
HUTCHINSON FRED CANCER US
DEEP MUTATIONAL
WO2020006494 RES
SCANNING LIBRARIES AND
UNIV WASHINGTON US
USES OF THE SAME
NOVEL PLATFORMS FOR
CO-STIMULATION, NOVEL
CAR DESIGNS AND OTHER
WO2019067805 UNIV SOUTHERN CALIFORNIA US
ENHANCEMENTS FOR
ADOPTIVE CELLULAR
THERAPY
DNA ANTIBODY
CONSTRUCTS FOR USE
WEINER DAVID US
WO2019067671 AGAINST MIDDLE EAST
SMITH TREVOR RF US
RESPIRATORY SYNDROME
CORONAVIRUS
UNIV NORTH CAROLINA US COMPOSITIONS AND
US2019023769 CHAPEL HILL METHODS FOR INHIBITING
UNIV JOHNS HOPKINS US PATHOGEN INFECTION
26DIAGNÓSTICO
Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
INDUSTRY ACADEMIC MONOCLONAL ANTIBODY
COOPERATION AGAINST S PROTEIN OF MERS-
WO2020036403 KR
FOUNDATION HALLYM CORONAVIRUS, AND USE OF
UNIV SAME
METHODS FOR REAL-TIME
MULTIPLEX ISOTHERMAL
US2020048722 NYAN DOUGBEH US DETECTION AND IDENTIFICATION
OF BACTERIAL, VIRAL, AND
PROTOZOAN NUCLEIC ACIDS
PRIMER PROBE MIXED LIQUID
DA AN GENE CO LTD OF AND KIT FOR DETECTING MIDDLE
CN110468237 CN
SUN YAT SEN UNIV EAST RESPIRATORY SYNDROME
CORONA VIRUS (MERS-COV)
WHOLE PROTEIN GENE OF MERS-
COV NUCLEOPROTEIN AND
KOREA RES INST
VACCINE COMPOSITION FOR
KR20190119391 BIOSCIENCE & KR
PREVENTING INFECTION OF
BIOTECHNOLOGY
MERS-COV COMPRISING THE
SAME
INDUSTRY ACADEMIC
AN ANTI-MERS-COV
COOPERATION
KR20190122283 KR MONOCLONAL ANTIBODY AND
FOUNDATION HALLYM
USE OF THE SAME
UNIV
NATIONAL INSTITUTE METHOD AND KIT FOR
KR102018201 OF ENVIRONMENTAL KR DETECTING BATCORONAVIRUS
RES USING REAL-TIME PCR
WUXI CUSTOMS DISTR CN
PEOPLES REPUBLIC OF
QUADRUPLE FLUORESCENCE
CHINA
QUANTITATIVE DETECTION KIT
INST FOR VIRAL DISEASE CN
FOR SIMULTANEOUSLY
CN110144422 CONTROL AND
DETECTING FOUR HUMAN
PREVENTION CHINESE
CORONAVIRUSES
CENTER FOR DISEASE
CONTROL AND
PREVENTION
27Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
KOREA CENTER FOR KR
DISEASE CONTROL AND A METHOD FOR DETECTING MERS
PREVENTION CORONAVIRUS USING MERS
KR102019008
KOREA RES INST KR CORONAVIRUS NUCLEOCAPSID
BIOSCIENCE & FUSION PROTEIN
BIOTECHNOLOGY
KOREA CENTER FOR S1 MONOCLONAL ANTIBODIES OF
KR102007161 DISEASE CONTROL AND KR SPECIFICALLY BINDING TO SPIKE
PREVENTION S1 PROTEIN OF MERS-COV
BINDING MOLECULE HAVING
NEUTRALIZING ACTIVITY AGAINST
WO2019151632 CELLTRION INC KR
MIDDLE EAST RESPIRATORY
SYNDROME-CORONAVIRUS
KOREA CENTER FOR KR
DISEASE CONTROL AND
PREVENTION PRETREATMENT METHOD OF
BIONOTE INC KR SPUTUM FOR DETECTING MIDDLE
KR20190078174
KOREA UNIV RESEARCH KR EAST RESPIRATORY SYNDROME
AND BUSINESS CORONAVIRUS
FOUNDATION SEJONG
CAMPUS
BROAD INST INC US
MASSACHUSETTS INST US CRISPR EFFECTOR SYSTEM BASED
WO2019126577
TECHNOLOGY MULTIPLEX DIAGNOSTICS
HARVARD COLLEGE US
MIDDLE EAST RESPIRATORY
JIANGSU UNINOVO SYNDROME CORONAVIRUS
CN109371174 BIOLOGICAL TECH CO CN FLUORESCENCE PCR
LTD (POLYMERASE CHAIN REACTION)
DETECTION KIT
ANTIBODY FOR MIDDLE EAST
RESPIRATORY SYNDROME
ATGEN CO LTD KR
WO2019078600 CORONAVIRUS, AND METHOD
UNIV YONSEI IACF KR
FOR MEASURING ANTIBODY
TITER BY USING SAME
METHOD FOR DETECTING
LANZHOU VETERINARY CN MICROORGANISMS THROUGH
RES INSTITUTE CHINESE SMALL RNA HIGH-THROUGHPUT
CN109355365 ACADEMY OF SEQUENCING
AGRICULTURE SCIENCES
UNIV NANKAI CN
NANTONG INT TRAVEL RESPIRATORY TRACT PATHOGEN
HEALTH CARE RAPID FLUORESCENCE PCR
CN109207639 CN
OUTPATIENT DETECTION KIT AND PRIMER
DEPARTMENT PROBE COMBINATION THEREOF
28Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
KOREA CENTER FOR KR
DISEASE CONTROL AND S2 MONOCLONAL ANTIBODIES OF
KR101969696 PREVENTION SPECIFICALLY BINDING TO SPIKE
OSONG MEDICAL KR S2 PROTEIN OF MERS-COV
INNOVATION FOUND
BROAD INST INC US
MASSACHUSETTS INST US CRISPR EFFECTOR SYSTEM BASED
WO2019071051
TECHNOLOGY DIAGNOSTICS
HARVARD COLLEGE US
N- C- NC NC FUSION PROTEIN
COMPRISING N-TERMINUS
DOMAIN FRAGMENTS AND C-
KOREA RES INST
TERMINUS DOMAIN FRAGMENTS
KR20190035542 BIOSCIENCE & KR
OF MERS-COV NUCLEOCAPSID
BIOTECHNOLOGY
PROTEIN AND KIT FOR
DIAGNOSING INFECTION OF
MERS-COV USING THE SAME
JAPAN HEALTH MONOCLONAL ANTIBODIES AND
JP2018203632 JP
SCIENCES FOUND ASSAY KITS
PRIMER SET FOR DETECTION OF
NAT UNIV CHUNGBUK
KR20180125141 KR MERS-CORONAVIRUS AND USES
IND ACAD COOP FOUND
THEREOF
SARS MERS PRIMER FOR
KOREA RES INST KR
SIMULTANEOUS DETECTION OF
BIOSCIENCE &
SARS-RELATED CORONA VIRUS
KR101916899 BIOTECHNOLOGY
AND MERS-RELATED CORONA
BIONANO HEALTH KR
VIRUS AND DETECTING METHOD
GUARD RES CENTER
USING THE SAME
MONOCLONAL ANTIBODY
AGAINST SPIKE PROTEIN OF
KOREA CENTER FOR
MIDDLE EAST RESPIRATORY
KR101895228 DISEASE CONTROL AND KR
SYNDROME CORONAVIRUS AND
PREVENTION
USES THEROF
BROAD INST INC US
MASSACHUSETTS INST US
TECHNOLOGY
HARVARD COLLEGE US
ABUDAYYEH OMAR US
GOOTENBERG US CRISPR EFFECTOR SYSTEM BASED
WO2018170340
JONATHAN DIAGNOSTICS FOR VIRUS
LANDER ERIC S US DETECTION
SABETI PARDIS US
FREIJE CATHERINE US
AMANDA US
MYHRVOLD CAMERON US
29Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
METHODS FOR REAL-TIME
MULTIPLEX ISOTHERMAL
US10072309 NYAN DOUGBEH CHRIS US DETECTION AND IDENTIFICATION
OF BACTERIAL, VIRAL, AND
PROTOZOAN NUCLEIC ACIDS
INST FOR VIRAL DISEASE
APPLICATION OF
CONTROL AND
PHENAZOPYRIDINE TO
PREVENTION CHINESE
CN108324715 CN PREPARATION OF BROAD-
CENTER FOR DISEASE
SPECTRUM ANTI-CORONAVIRUS
CONTROL AND
MEDICINE
PREVENTION
BIONEER CORP KR COMPOSITION FOR DETECTION
KOREA CENTER FOR KR OF MERS-COV DETECTION
KR101886274
DISEASE CONTROL AND METHOD COMPRISING THE
PREVENTION COMPOSITION AND KIT THEREOF
BIONEER CORP KR COMPOSITION FOR DETECTION
KOREA CENTER FOR KR OF MERS-COV DETECTION
KR101886272
DISEASE CONTROL AND METHOD COMPRISING THE
PREVENTION COMPOSITION AND KIT THEREOF
BROAD INST INC US
MASSACHUSSETTS US CRISPR EFFECTOR SYSTEM BASED
WO2018107129
INSTITUTE OF TECH DIAGNOSTICS
HARVARD COLLEGE US
QUINAZOLINONES AND
FORMA THERAPEUTICS AZAQUINAZOLINONES AS
US2018162835 US
INC UBIQUITIN-SPECIFIC PROTEASE 7
INHIBITORS
PRIMER SET FOR DETECTION OF
NAT UNIV CHUNGBUK
KR20180052317 KR MERS-CORONAVIRUS AND USES
IND ACAD COOP FOUND
THEREOF
PRIMERS AND PROBE FOR
KOGENE BIOTECH CO KR DETECTION OF MIDDLE EAST
LTD RESPIRATORY SYNDROME
KR101857684 KOREA CENTER FOR KR CORONAVIRUS AND DETECTING
DISEASE CONTROL AND METHOD FOR MIDDLE EAST
PREVENTION RESPIRATORY SYNDROME
CORONAVIRUS USING THE SAME
METHOD AND KIT FOR
JAPAN SCIENCE & TECH
WO2018043733 JP DETECTING PATHOGENIC
AGENCY
MICROORGANISM
A ANTIBODY ABLE TO
NEUTRALIZE MIDDLE EAST
KR101828794 CELLTRION INC KR
RESPIRATORY SYNDROME
CORONAVIRUS
30Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
FLUORESCENT RT-RAA (REVERSE
TRANSCRIPTION RECOMBINASE
AID AMPLIFICATION) PRIMER
NINGBO INT TRAVEL FOR DETECTING MERS-COV
CN107557496 CN
HEALTH CARE CENTER (MIDDLE EAST RESPIRATORY
SYNDROME CORONAVIRUS),
PROBE AND DETECTING
METHOD
PRIMER PROBE SET, KIT AND
DETECTION METHOD FOR
DETECTING SARS-COV (SEVERE
BEIJING APPLIED
ACUTE RESPIRATORY
CN108060266 BIOLOGICAL TECH CO CN
SYNDROME CORONAVIRUS)
LTD
AND MERS-COV (MIDDLE EAST
RESPIRATORY SYNDROME
CORONAVIRUS)
- METHOD FOR DETECTING A
DIAGNOSTIC MARKER FOR
SAMSUNG LIFE PUBLIC
KR20190131380 KR INFECTIOUS DISEASE BASED ON
WELFARE FOUNDATION
SURFACE-ENHANCED RAMAN
SCATTERING
MERS MIDEAST RESPIRATORY
SYNDROME AND SEVERE ACUTE
RESPIRATORY SYNDROME
KR20200007980 CHO HAN JUN KR BIOMARKERS AND CANDIDATE
COMPOUNDS FOR THE
DEVELOPMENT OF MERS CURE
FLUOROGENIC PROBES AND
THEIR USE IN QUANTITATIVE
US2018002743 JAN BIOTECH INC US
DETECTION OF TARGET RNA
SEQUENCES
COMPOSITIONS AND METHODS
US2018371526 UNIV ARIZONA STATE US FOR DETECTING VIRAL NUCLEIC
ACIDS
COMPOSITION AND METHOD
FOR IMPROVING SENSITIVITY
UNIV ULSAN FOUND KR AND SPECIFICITY OF DETECTION
WO2018048194 IND COOP OF NUCLEIC ACIDS USING
ASAN FOUND KR DCAS9 PROTEIN AND GRNA
BINDING TO TARGET NUCLEIC
ACID SEQUENCE
METHODS AND SYSTEMS FOR
COYOTE BIOSCIENCE CO
WO2018086023 CN CONDUCTING CHEMICAL OR
LTD
BIOLOGICAL REACTION
31Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
SYSTEMS AND METHODS FOR
COYOTE BIOSCIENCE CO
WO2019144966 CN ANALYZING NUCLEIC ACIDS
LTD
TELEKOM MALAYSIA MY
BERHAD
METHOD OF MEASURING BODY
MY167532
TEMPERATURE
UNIV TELEKOM SDN MY
BHD
COMPOSITIONS, SYSTEMS, KITS,
SYNTHETIC GENOMICS
WO2019094969 US AND METHODS FOR MODIFYING
INC
RNA
APPLICATION OF TIM-3
INTERACTION WITH NF90 IN
CN109266731 DOU SHUAIJIE CN PRODUCTS FOR THE PREVENTION
OR TREATMENT OF VIRAL
INFECTION
UNIV INDUSTRY KR
COOPERATION GROUP S2 A METHOD FOR PRODUCING
KR20190000009 KYUNG HEE UNIV MERS ANTIGEN USING
DROSOPHILA MELANOGASTOR S2
BOREDA BIOTECH KR
FLOW CYTOMETRY SYSTEM AND
FLOWMETRIC LIFE
WO2018223151 US METHODS FOR THE DIAGNOSIS
SCIENCES INC
OF INFECTIOUS DISEASE
A PROCESS FOR
MANUFACTURING POROUS
SILICA PARTICLES LOADED WITH
AT LEAST ONE BIOACTIVE
WO2018202818 NANOLOGICA AB SE
COMPOUND ADAPTED FOR
LUNG, NASAL, SUBLINGUAL
AND/OR PHARYNGEAL DELIVERY
COMPOSITIONS AND METHODS
DANA FARBER CANCER
WO2018145075 US FOR AUGMENTING ANTIBODY
INST INC
MEDIATED RECEPTOR SIGNALING
UNIV KOREA RES & BUS GLOVES FOR INFECTIOUS DISEASE
KR20180027929 KR
FOUND DIAGNOSTIC
METHODS FOR QUANTITATING
WO2018034885 REGENERON PHARMA US INDIVIDUAL ANTIBODIES FROM A
MIXTURE
GENMAB AS DK MULTISPECIFIC ANTIBODIES
WO2018011421
BIONTECH AG DE AGAINST CD40 AND CD137
CELL-STORED BARCODED DEEP
HUTCHINSON FRED US
MUTATIONAL SCANNING
WO2020006494 CANCER RES
LIBRARIES AND USES OF THE
UNIV WASHINGTON US
SAME
32Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
HUMAN ANTIBODIES TO MIDDLE
EAST RESPIRATORY SYNDROME -
US2019351049 REGENERON PHARMA US
CORONAVIRUS SPIKE PROTEIN
UNIV NORTH CAROLINA US COMPOSITIONS AND METHODS
US2019023769 CHAPEL HILL FOR INHIBITING PATHOGEN
UNIV JOHNS HOPKINS US INFECTION
RELIANT IMMUNE BIOFLUIDIC TRIGGERING SYSTEM
US2019148014 US
DIAGNOSTICS INC AND METHOD
33DISPOSITIVOS PARA EL TRATAMIENTO O CONTROL
DE LA INFECCIÓN VÍRICA
Nº
SOLICITANTE PAÍS CONTENIDO TÉCNICO
PUBLICACIÓN
KR 102028044 KIM PHIL LIP KR A Mask with breathing assembly
UNIV KWANGWOON IND
KR 20190041374 KR Plasma Emitting Diode Devices
ACAD COLLAB
CHAMBERS ANITA Recursive multi-tiered health
US 10302318 US
MARGARETTE isolation facility
SMART OPTIC CONTROLLER FOR
US 2018272023 HGI IND INC US
A HYDROXYL GENERATOR UNIT
KR 20180089206 WOSEM CO LTD KR Laboratory safety damper
DEVICE AND METHOD FOR
TREATMENT OF INFLAMMATION
RTT MOLECULAR DX USA BY EXTRACORPOREAL
WO 2018144505 US
INC PERIPHERAL BLOOD FILTRATION
FOR SPECIFIC REMOVAL OF
INFLAMMATION FACTORS
APPARATUS AND METHOD FOR
MONITORING A DISEASE AREA
UNIV SEOUL IND COOP
KR 101885031 KR AND PROVIDING AN
FOUND
INFORMATION BASED ON A
TRAFFIC NETWORK
KOREA ELECTRONICS Portable Virus Detection Device
KR 20180064705 KR
TECHNOLOGY using Mobile Phone
UNIV KOREA RES & BUS Gloves for infectious disease
KR 20180027929 KR
FOUND diagnostic
DAINIPPON PRINTING HEALTH STATE MANAGEMENT
JP 2018000278 JP
CO LTD SYSTEM
RELIANT IMMUNE BIOFLUIDIC TRIGGERING SYSTEM
US 2019148014 US
DIAGNOSTICS INC AND METHOD
34También puede leer
